Zobrazeno 41 - 50
of 100
pro vyhledávání: '"Michaela Mattheus"'
Autor:
Bernard Zinman, Christoph Wanner, Ivana Ritter, Michaela Mattheus, Silvio E. Inzucchi, Bettina J Kraus, Audrey Koitka-Weber, Hiddo J.L. Heerspink, David Z.I. Cherney, George L. Bakris, Matthew R. Weir, Maximilian von Eynatten, Naveed Sattar
Publikováno v:
Diabetes. 69
In EMPA-REG OUTCOME, empagliflozin (EMPA) reduced the risk of CV death by 38% in T2D patients (pts) with CV disease. EMPA induces an initial, reversible dip in estimated glomerular filtration rate (eGFR). We investigated whether this transient initia
Autor:
Julio Rosenstock, Egon Pfarr, Nikolaus Marx, Mark A. Espeland, Darren K. McGuire, Michaela Mattheus, Jyothis T. George, Odd Erik Johansen, Bernard Zinman
Publikováno v:
Diabetes. 69
CAROLINA® (CARdiovascular Outcome Study of LINAgliptin Versus Glimepiride in Type 2 Diabetes) was a randomized controlled clinical trial designed to compare the effects of linagliptin (LINA) with glimepiride (GLIM) on CV events and other outcomes in
Autor:
Julio Rosenstock, Egon Pfarr, Nikolaus Marx, Thomas Meinicke, Bernard Zinman, Odd Erik Johansen, Steven E. Kahn, Jyothis T. George, Darren K. McGuire, Mikkel Hoeiberg, Mark A. Espeland, Michaela Mattheus
Publikováno v:
Diabetes. 69
Treatment guideline recommendations for individuals with cardiovascular (CV) disease and type 2 diabetes (T2D) focus on medications with proven CV benefits. However, considerations relating to avoidance of hypoglycemia (HYPO) remain important. We rep
Autor:
David Z.I. Cherney, Audrey Koitka-Weber, Ivana Ritter, Christoph Wanner, Maximilian von Eynatten, Michaela Mattheus, Silvio E. Inzucchi, Bettina J Kraus, Bernard Zinman, Hiddo J.L. Heerspink, Naveed Sattar, George L. Bakris, Matthew R. Weir
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims Empagliflozin (EMPA) reduces cardiovascular and renal risk in patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD). EMPA induces an initial ‘dip’ in estimated glomerular filtration rate (eGFR). Alth
Autor:
Michaela Mattheus, Subodh Verma, Bernard Zinman, Abhinav Sharma, Silvio E. Inzucchi, Christoph Wanner, Anne Pernille Ofstad, David Fitchett, Lawrence A. Leiter, Jyothis T. George
Publikováno v:
Diabetes. 69
In the EMPA-REG OUTCOME trial, in patients with type 2 diabetes (T2D) with established atherosclerotic cardiovascular disease (ASCVD), empagliflozin reduced the risk of hospitalization for HF (HHF) by 35% (HR [95%CI] 0.65 [0.50-0.85]), CV death/HHF b
Autor:
Yutaka Seino, Bernard Zinman, Richard E. Pratley, Annett Keller, Darren K. McGuire, Michaela Mattheus, Mark A. Espeland, Nikolaus Marx, Odd Erik Johansen, Takashi Kadowaki, Knut Robert Andersen, Julio Rosenstock
Publikováno v:
Diabetes. 69
Older people with T2D have a high prevalence of comorbidities, frailty and polypharmacy. We investigated the effects of linagliptin (LINA) 5 mg versus glimepiride (GLIM) 1-4 mg once daily across age groups in the CARdiovascular Outcome Study of LINAg
Autor:
Bernard Zinman, Empa-Reg Outcome Investigators, Jyothis T. George, Maximilian von Eynatten, Michaela Mattheus, Silvio E. Inzucchi, Audrey Koitka-Weber, Sibylle Hauske, Christoph Wanner
Publikováno v:
Diabetes, obesitymetabolismREFERENCES. 22(12)
Aim To explore the cardiovascular (CV) and kidney effects of empagliflozin in patients with different clinical phenotypes of diabetic kidney disease (DKD) (i.e. with the presence or absence of overt albuminuria) participating in the EMPA-REG OUTCOME
Autor:
Jyothis T. George, Maximilian von Eynatten, Michaela Mattheus, Bernard Zinman, Uli C. Broedl, David Fitchett, Silvio E. Inzucchi, Christoph Wanner, John M. Lachin, Hans-Juergen Woerle
Publikováno v:
Circulation. 137:119-129
Background: Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus and established cardiovascular disease in the EMPA-REG OUTCOME trial (Empagliflozin Cardio
Autor:
Christoph Wanner, John M. Lachin, Philippe van de Borne, Uli C. Broedl, Bernard Zinman, Odd Erik Johansen, David Fitchett, Empa-Reg Outcome Investigators, Jyothis T. George, Hans-Juergen Woerle, Michaela Mattheus, Silvio E. Inzucchi
Publikováno v:
Journal of the American College of Cardiology. 71:364-367
Diabetes is associated with a significant decrease in life expectancy [(1)][1]. In the EMPA-REG OUTCOME trial ([NCT01131676][2]), empagliflozin given in addition to standard of care reduced the risk of cardiovascular death by 38% (hazard ratio [HR]:
Autor:
Odd Erik Johansen, Jolien Janssen, Stefan L.C. Geijselaers, Esther van den Berg, Mark A. Espeland, Michaela Mattheus, Bernard Zinman, Geert Jan Biessels
Publikováno v:
Diabetes Care, 42(1), E1-E3. American Diabetes Association Inc.
Diabetes Care, 42(1), e1. American Diabetes Association Inc.
Diabetes Care, 42(1), e1. American Diabetes Association Inc.
Cognitive dysfunction is increasingly recognized as a complication of type 2 diabetes. There is a growing evidence for etiologic roles of glycemia and insulin resistance, although important questions remain (1,2). Elevated levels of glycosylated hemo